Go to main content

​​

CRISP – Communicating RISks associated with cardiometabolic conditions in Pregnancy

​In recent decades, research has increasingly focused on how early-life factors, including maternal behaviour during pregnancy, influence a child’s risk of developing obesity, diabetes, and cardiovascular disease later in life. Research also indicates that women who experience cardiometabolic conditions during pregnancy, such as gestational diabetes and pre-eclampsia, have an increased risk of later development of diabetes and cardiovascular disease. This underscores pregnancy as a crucial period for prevention and health promotion, but it also presents challenges in how health risks are communicated.​​​

​About the Project

The CRISP project investigates how risks associated with cardiometabolic conditions during pregnancy can be communicated without inducing unnecessary fear, stigmatisation, and medicalisation. This is examined through a series of sub-studies, including an interview study and a survey with the affected women, focusing on their risk perception, communication preferences, needs, challenges, and specific experiences with risk communication during pregnancy.

In collaboration with healthcare professionals and women with cardiometabolic conditions during pregnancy, we will develop a tailored tool with guidelines and specific recommendations for risk communication, to be used in visual, oral, and written dissemination. The tool will then be pilot-tested.

O​​​bjec​​​​tives

The aim is to explore how risks associated with cardiometabolic conditions during pregnancy can be communicated without inducing stigmatisation or medicalisation.

The project has four components:

  1. A qualitative study of risk perception among women with cardiometabolic conditions during pregnancy.

  2. A quantitative study of risk perception, communication preferences, and needs among women with cardiometabolic conditions during pregnancy.

  3. Development of a risk communication tool in collaboration with healthcare professionals and women with current or previous cardiometabolic conditions in pregnancy.

  4. Pilot testing of the tool.​

C​ollabo​r​​​ators

  • Rigshospitalet

  • Steno Diabetes Center Aarhus 


Last updated:
Responsible editor
Stenos webteam
Klik for at scrolle op eller ned p� siden G� til toppen af siden